Lonza strengthens ADC offering with Synaffix acquisition

Lonza has acquired Synaffix B.V., a biotech company focused on commercializing its clinical-stage technology platform for the development of antibody drug conjugates (ADCs).

Related Keywords

Netherlands ,Ulrich Osswald , ,Markets Amp Regulations ,Antibody Drug Conjugates ,Ntibody ,Monza ,Manufacturing ,